Cargando…
Three decades of progress from surgery to medical therapy for isolated neuroaxis BRAF V600E–positive Langerhans cell histiocytosis management: illustrative case
BACKGROUND: “Langerhans cell histiocytosis” (LCH) is a term that encompasses single-system or multisystem disorders traditionally characterized by a proliferation of clonal CD1a+/CD207+ myeloid-derived histiocytes. In most cases of LCH, mitogen-activated protein kinase (MAPK) pathway somatic mutatio...
Autores principales: | Muthiah, Nallammai, Nowicki, Kamil W., Picarsic, Jennifer L., D’Angelo, Michael P., Marker, Daniel F., Andrews, Edward G., Monaco, Edward A., Niranjan, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Neurological Surgeons
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245772/ https://www.ncbi.nlm.nih.gov/pubmed/35854832 http://dx.doi.org/10.3171/CASE2118 |
Ejemplares similares
-
Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020) -
BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016) -
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
por: Bates, Sara V., et al.
Publicado: (2013) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)